Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Stifel Reiterates Buy Rating on Apellis Pharmaceuticals (APLS), 'we think the entire package presents a relatively convincing picture'
August 9, 2022 4:02 AM EDTStifel analyst Annabel Samimy reiterated a Buy rating and $60.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).
The analyst comments "While we await a seminal decision on pegcetacoplan in GA (11/26/22), APLS continues to execute on the Empaveli/PNH commercial launch, with sales reaching $16.3mn/Cons.... More
Cowen Reiterates Outperform Rating on Apellis Pharmaceuticals (APLS), 'We Remain Optimistic For Pegcetacoplan Approval'
August 9, 2022 4:01 AM EDTCowen analyst Phil Nadeau reiterated an Outperform rating and $70.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).
The analyst comments "We continue to view the acceptance, granting of Priority Review for the sNDA for pegcetacoplan in GA and the fact that the... More
Roth Capital Reiterates Sell Rating on Apellis Pharmaceuticals (APLS), Street Low $40 PT
August 9, 2022 3:58 AM EDTRoth Capital analyst Elemer Piros reiterated a Sell rating and $40.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).
The analyst comments "We arrive at our 12-month price target of $40/share by assessing the after-tax, risk-adjusted NPV of potential future cash flows from pegcetacoplan for treatment PNH... More
